Related Experiment Video
Updated: Feb 16, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Regulatory T cells for tolerance
Kento Kawai1, Masateru Uchiyama1, Joanna Hester1
1Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Level 6, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Regulatory T cells (Tregs) are critical mediators of immune homeostasis and hold significant promise in the quest for transplantation tolerance. Progress has now reached a critical threshold as techniques for production of clinical therapies are optimised and Phase I/II clinical trials are in full swing. Initial safety and efficacy data are being reported, with trials assessing a number of different strategies for the introduction of Treg therapy. It is now more crucial than ever to elucidate further the function and behaviour of Tregsin vivoand ensure safe delivery. This review will discuss the current state of the art and future directions in Treg therapy.
Regulatory T cells (Tregs) are critical mediators of immune homeostasis and hold significant promise in the quest for transplantation tolerance. Progress has now reached a critical threshold as techniques for production of clinical therapies are optimised and Phase I/II clinical trials are in full swing. Initial safety and efficacy data are being reported, with trials assessing a number of different strategies for the introduction of Treg therapy. It is now more crucial than ever to elucidate further the function and behaviour of Tregsin vivoand ensure safe delivery. This review will discuss the current state of the art and future directions in Treg therapy.
Related Concept Videos
Cis-regulatory Sequences
Cis-regulatory Sequences
Global Regulatory Systems
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Control Governance: Regulatory Bodies and Their Impact
Cell Specific Gene Expression

